Abstract：Objective To explore the clinical effect of Levosimendan in the treatment of chronic heart failure(CHF)in the elderly.Methods Seventy-two elderly patients with CHF treated in our hospital from February 2017 to February 2019 were selected as the research subjects.The patients were divided into the conventional group and the Levosimendan group according to the random number table method,with 36 patients in each group.In the conventional group,regular treatment was used,and in the Levosimendan group,regular treatment combined with Levosimendan was adopted.The serological indicators,cardiac structure,and clinical treatment effect of the two groups were analyzed.Results After 12 and 24 weeks of treatment,the heart fatty acid binding protein(H-FABP),cardiac troponin I(cTnI),aminoterminal brain natriuretic peptide precursor(NT-proBNP),and endothelium-1(ET-1),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),and serum matrix metalloproteinase-9(MMP-9)in the Levosimendan group were lower than those in the conventional group,and the differences were statistically significant(P＜0.05).The nitric oxide(NO),left ventricular ejection fraction(LVEF)and insulin-like growth factor-1(IGF-1)in the levosimendan group were higher than those in the conventional group,the differences were statistically significant(P＜0.05).The total effectiveness rate of treatment in the levosimendan group was higher than that in the conventional group,the difference was statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Levosimendan can improve the clinical efficacy of CHF in the elderly,which has a good application effect.
张伟华; 邱伟林; 李志龙. 左西孟旦治疗老年慢性心力衰竭的临床效果[J]. 中国当代医药, 2020, 27(10): 46-49.
ZHANG Wei-hua; QIU Wei-lin; LI Zhi-long. Clinical effect of Levosimendan in the treatment of chronic heart failure in the elderly. 中国当代医药, 2020, 27(10): 46-49.
京公网安备 11010502046607号